

DAFTAR PUSTAKA

- Agristika, A., & Carolia, N. (2017). Agonis Reseptor GLP 1 untuk terapi Diabetes Mellitus Tipe 2. *JAgromedUnila*.
- Alonso, R., Fariás, M., Alvarez, V., & Cuevas, A. (2016). The Genetics of Obesity. In *Translational Cardiometabolic Genomic Medicine*.
- Crane, J., & McGowan, B. (2016). *The GLP-1 agonist , liraglutide , as a pharmacotherapy for obesity*. 92–107.
- Detriffoni-Melo, A. T., Demonte-Alegre, F. A., Leandro-Merhi, V. A., & Diez-Garcia, R. W. (2019). Additional abdominal measurements are a useful tool to evaluate body composition in obese women. *Arquivos de Gastroenterologia*.
- Evans, M., Billings, L. K., Håkan-Bloch, J., Slothuus, U., Abrahamsen, T. J., Andersen, A., & Jansen, J. P. (2018). An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. *Journal of Medical Economics*.
- Gallo, M. (2013). Thyroid safety in patients treated with liraglutide. In *Journal of Endocrinological Investigation*.
- Gupta, S. R. N. (2014). Body Composition Analysis of Staff members of College Using Bioelectrical Impedance Analysis Method. *International Journal of Chemical Engineering and Applications*.
- Halawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., Zinsmeister, A. R., & Camilleri, M. (2017). Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. *The Lancet Gastroenterology and Hepatology*.
- Ishii, S., Nagai, Y., Sada, Y., Fukuda, H., Nakamura, Y., Matsuba, R., ... Tanaka, Y. (2019). Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series. *Journal of Clinical Medicine Research*, 11(3), 219–224.
- Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016). Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. *Clinical Pharmacokinetics*, 55(6), 657–672.

- Jensen, T. M., Saha, K., & Steinberg, W. M. (2015). Is there a link between liraglutide and pancreatitis? A post Hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. *Diabetes Care*, 38(6), 1058–1066.
- Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020). A randomized, controlled trial of liraglutide for adolescents with obesity. *New England Journal of Medicine*.
- Kemenkes RI. (2018). *HASIL UTAMA RISKESDAS 2018*.
- Lyons-Reid, J., Ward, L. C., Kenealy, T., & Cutfield, W. (2020). Bioelectrical impedance analysis—an easy tool for quantifying body composition in infancy? In *Nutrients*.
- Mantzorou, M., Tolia, M., Poultsidi, A., Pavlidou, E., Papadopoulou, S. K., Papandreou, D., & Giaginis, C. (2020). Can bioelectrical impedance analysis and BMI be a prognostic tool in head and neck cancer patients? A review of the evidence. In *Cancers*.
- Naderpoor, N., Shorakae, S., Joham, A., Boyle, J., De Courten, B., & Teede, H. J. (2015). Obesity and polycystic ovary syndrome. In *Minerva endocrinologica*.
- Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., Le Roux, C. W., Ortiz, R. V., Jensen, C. B., & Wilding, J. P. H. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *New England Journal of Medicine*, 373(1), 11–22.
- Riskesdas. (2018). Riset Kesehatan Dasar. *Riset Kesehatan Dasar*.
- Rondanelli, M., Perna, S., Astrone, P., Grugnetti, A., Solerte, S. B., & Guido, D. (2016). Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. *Patient Preference and Adherence*, 10, 407–413.
- Samsell, L., Regier, M., Walton, C., & Cottrell, L. (2014). Importance of Android/Gynoid Fat Ratio in Predicting Metabolic and Cardiovascular Disease Risk in Normal Weight as well as Overweight and Obese Children. *Journal of Obesity*, 2014.
- Santilli, F., Simeone, P. G., Guagnano, M. T., Leo, M., Maccarone, M. T., Castelnovo, A. Di, ... Consoli, A. (2017). Effects of liraglutide on weight loss, fat distribution, and b-cell function in obese subjects with prediabetes or early type 2 diabetes. In *Diabetes Care* (Vol. 40, hal.

1556–1564). American Diabetes Association Inc.

Serodio, K. J., Ardern, C. I., Rotondi, M. A., & Kuk, J. L. (2014). Tricyclic and SSRI usage influences the association between BMI and health risk factors. *Clinical Obesity*, 5, n/a-n/a.

Sherwood, L. (2014). Fisiologi Manusia : Dari Sel ke Sistem (Introduction to Human Physiology). *Penerbit Buku Kedokteran EGC*.

Sugondo, S. (2014). *Buku Ajar Ilmu Penyakit Dalam. Ilmu Penyakit Dalam (VI)*. Jakarta: Interna Publishing.

Suzuki, D., Toyoda, M., Kimura, M., Miyauchi, M., Yamamoto, N., Sato, H., Tanaka, E., Kuriyama, Y., Miyatake, H., Abe, M., Umezono, T., & Fukagawa, M. (2013). Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. *Internal Medicine*.

Thompson, A. K., Miniñane, A. M., & Williams, C. M. (2011). Trans fatty acids and weight gain. In *International Journal of Obesity*.

Torres, S. J., & Nowson, C. A. (2007). Relationship between stress, eating behavior, and obesity. In *Nutrition*.

UNICEF. (2012). The State of the World's Children in 2012: Children in an Urban World. In *The State of the World's Children in 2012*.

